GlassScriptPhysician profile
Janet Chin
NPI 1205862653
$8,587.82
in general payments reported to CMS, 2019-2025
15 companies · $5,477 in 2025
The $5,477 reported for 2025 was more than what 83% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $39.60 · 2021: $184 · 2022: $267 · 2023: $192 · 2024: $2,428 · 2025: $5,477.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,973 · Honoraria: $1,700 · Food and Beverage: $1,365 · Travel and Lodging: $46.00 · Education: $13.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,972.50 |
| Honoraria | $1,700.00 |
| Food and Beverage | $1,364.72 |
| Travel and Lodging | $46.00 |
| Education | $13.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Deciphera Pharmaceuticals INC. | $3,546.60 | 2024-2025 | Vimseltinib, Qinlock |
| Ipsen Biopharmaceuticals, INC | $3,501.55 | 2025 | Tazverik |
| Astrazeneca Pharmaceuticals LP | $504.18 | 2024-2025 | Imfinzi |
| Steris Corporation | $244.53 | 2024 | |
| Gilead Sciences, INC. | $178.34 | 2021-2025 | Trodelvy |
| Pfizer INC. | $157.37 | 2021-2023 | |
| Abbvie INC. | $95.00 | 2022-2024 | Venclexta |
| Genentech USA, INC. | $93.89 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $64.33 | 2019-2022 | |
| Glaxosmithkline, LLC. | $61.63 | 2022-2023 | Zejula, Jemperli |
| Pharmacyclics LLC, An Abbvie Company | $39.67 | 2021 | |
| Blueprint Medicines Corporation | $32.29 | 2023 | Ayvakit |
| Stemline Therapeutics INC. | $27.51 | 2025 | Orserdu |
| Janssen Biotech, INC. | $23.08 | 2022 | |
| Cti Biopharma Corp. | $17.85 | 2023 | Vonjo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janet Chin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.